Efficacy of Biocides against Gram-negative Bacteria. Dr. Peter Goroncy-Bermes R & D Department

Größe: px

Ab Seite anzeigen:

Download "Efficacy of Biocides against Gram-negative Bacteria. Dr. Peter Goroncy-Bermes R & D Department"

Reiner Geisler
vor 5 Jahren
Abrufe

1 against Gram-negative Bacteria Dr. Peter Goroncy-Bermes R & D Department

2 Three important groups of weapons can be used to fight infectious agents Antibiotics Antimycotics Biocides Titel der Präsentation Schülke & Mayr GmbH Seite 2

3 Titel der Präsentation Schülke & Mayr GmbH Seite 3

4 Available biocides Cationic compounds (benzalkoniumchloride, octenidine, guanidine, chlorhexidine) Alcohols Aldehydes Peroxides Chlorine compounds Amines Titel der Präsentation Schülke & Mayr GmbH Seite 4

5 Antimicrobial spectrum of different biocides b + b - myc f v env. v nonenv. s Active oxygen Aldehydes Chlorine (chlorinereleasing compound) Alcohols (ready-to-use) o - Phenols Amines + o Cationics / Amphoterics + o o = effective o = more or less - = not effective Titel der Präsentation Schülke & Mayr GmbH Seite 5

6 Cationic Active Ingredients are very popular with the users Good skin compatibility Good material compatibility No smell Limited antimicrobial activity Incompatible with soaps and anionic surfactants Titel der Präsentation Schülke & Mayr GmbH Seite 6

7 Test product A (concentrate of a surface disinfectant): contains 22 g benzalkoniumchloride, 17 g 2-phenoxyethanol, 0.9 g aminoalkylglycine in 100 g solution Test organisms Clinical isolates of Klebsiella pneumoniae (4 strains, 1 strain ESBL producer) from a Dutch hospital Method The antimicrobial activity was evaluated in a suspension test according to EN under dirty conditions Results All strains were sufficiently killed (> 5 lg reduction) at 0.5% and 15 min contact time or 0.75% in 5 min contact time Titel der Präsentation Schülke & Mayr GmbH Seite 7

8 Klebsiella pneumoniae 3129, ESBL producer Klebsiella pneumoniae Titel der Präsentation Schülke & Mayr GmbH Seite 8

9 Klebsiella pneumoniae 4022 Klebsiella pneumoniae Titel der Präsentation Schülke & Mayr GmbH Seite 9

Lg Reduction Efficacy of Biocides 7 6 5 4 3 2 1 0 Antimicrobial activity of test product A with phenoxyethanol (a) and without phenoxyethanol (b) Test organism: P.

10 Lg Reduction Efficacy of Biocides Antimicrobial activity of test product A with phenoxyethanol (a) and without phenoxyethanol (b) Test organism: P. aeruginosa 2,5 4,1 0,2 0,2 1,9 3,1 2,1 5 6,2 0,2 4,24,4 0.25% a 0.25% b 0.50% a 0.50% b Use Concentration 5 min 15 min 30 min Titel der Präsentation Schülke & Mayr GmbH Seite 10

11 Test product B (ready-to-use surface disinfectant): contains 3 different QACs, each 0.26 g/100 g solution Test organisms (clinical isolates) Escherichia coli 02, ESBL producer Escherichia coli 08, ESBL producer Klebsiella pneumoniae 01, ESBL producer Klebsiella pneumoniae 52, ESBL producer Method The antimicrobial activity was evaluated in a suspension test according to EN under dirty conditions Titel der Präsentation Schülke & Mayr GmbH Seite 11

12 Escherichia coli ESBL strain Titel der Präsentation Schülke & Mayr GmbH Seite 12

13 Klebsiella pneumoniae ESBL strain Titel der Präsentation Schülke & Mayr GmbH Seite 13

01, ESBL producer Klebsiella pneumoniae 52, ESBL producer Method The antimicrobial activity was evaluated in a

14 Test product C (instrument disinfectant): contains 11 g succine dialdehyde and 3 g dimethoxytetrahydrofuran in 100 g solution Test organisms Escherichia coli 02, ESBL producer Escherichia coli 08, ESBL producer Klebsiella pneumoniae 01, ESBL producer Klebsiella pneumoniae 52, ESBL producer Method The antimicrobial activity was evaluated in a suspension test according to EN under dirty conditions Titel der Präsentation Schülke & Mayr GmbH Seite 14

15 Escherichia coli ESBL strain Titel der Präsentation Schülke & Mayr GmbH Seite 15

16 Klebsiella pneumoniae ESBL strain Titel der Präsentation Schülke & Mayr GmbH Seite 16

Use recommendation 5% - 15 min 4% - 30 min 2% - 60 min 30.

17 Use recommendation 5% - 15 min 4% - 30 min 2% - 60 min Titel der Präsentation Schülke & Mayr GmbH Seite 17

18 Titel der Präsentation Schülke & Mayr GmbH Seite 18

19 Weber D J et al. Antimicrob. Agents Chemother. 2007, 51: Titel der Präsentation Schülke & Mayr GmbH Seite 19

20 Titel der Präsentation Schülke & Mayr GmbH Seite 20

21 Titel der Präsentation Schülke & Mayr GmbH Seite 21

22 Titel der Präsentation Schülke & Mayr GmbH Seite 22

23 Titel der Präsentation Schülke & Mayr GmbH Seite 23

24 Antimicrobial activity of 5 disinfectants against a clinical isolate of Serratia marcescens in a quantitative suspension test (VAH) under clean conditions Product A: 3 different QACs (0.78 g/100 g) ( 89% of squeezed solution) Product B: 2 different QACs (0.8 g/100 g) (89% of squeezed solution) Product C: 2 different QACs (0.75 g /100 g) (89% of squeezed solution) Product D: Peracetic acid (0.06 g/100 g) (solution) Product E: 25 g ethanol (94%) and 35 g 1-Propanol per 100 g Titel der Präsentation Schülke & Mayr GmbH Seite 24

Lg Reduction Efficacy of Biocides 6 Antimicrobial activity of 5 disinfectants against a clinical isolate of Serratia marcescens in a quantitative suspension test

25 Lg Reduction Efficacy of Biocides 6 Antimicrobial activity of 5 disinfectants against a clinical isolate of Serratia marcescens in a quantitative suspension test under clean conditions 6.25% 50% s 30 min 1 0 Product A Product B Product C Product D Product E Titel der Präsentation Schülke & Mayr GmbH Seite 25

26 Titel der Präsentation Schülke & Mayr GmbH Seite 26

27 Conclusion Effective biocides are still available. But how long? Usually, multi-resistant Gram-negative bacteria are not more resistant to disinfectants than sensitive strains Disinfectants that do not smell and are skin and material friendly such as QACs are sometimes not sufficient to fight pathogens Stronger active ingredients with a broad spectrum are also needed Titel der Präsentation Schülke & Mayr GmbH Seite 27

Ähnliche Dokumente

THE RIGHT CHOICE. Dr. Béatrice Grabein Department Clinical Microbiology and Infection Prevention University Hospital Munich

THE RIGHT CHOICE. Dr. Béatrice Grabein Department Clinical Microbiology and Infection Prevention University Hospital Munich CAMPUS GROSSHADERN CAMPUS INNENSTADT THE RIGHT CHOICE Dr. Béatrice Grabein Department Clinical Microbiology and Infection Prevention University Hospital Munich Mortality (%) INADEQUATE ANTIMICROBIAL THERAPY